A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma.

伦瓦提尼 医学 肿瘤科 内科学 黑色素瘤 临床终点 队列 不利影响 酪氨酸激酶抑制剂 临床研究阶段 索拉非尼 毒性 胃肠病学 临床试验 癌症研究 癌症 肝细胞癌
作者
Steven O’Day,René González,Kevin Kim,Bartosz Chmielowski,Richard Kefford,Georgina V. Long,Carmen Loquai,C. Lance Cowey,Axel Hauschild,John D. Hainsworth,Peter Hersey,Frances Boyle,T.R. Jeffry Evans,Omid Hamid,Nicole Meneses,Corina Andresen,Min Ren,James P. O’Brien,Keith T. Flaherty
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:31 (15_suppl): 9026-9026 被引量:11
标识
DOI:10.1200/jco.2013.31.15_suppl.9026
摘要

9026 Background: Lenvatinib is an oral receptor tyrosine kinase inhibitor targeting VEGFR1-3, FGFR1-4, RET, KIT, and PDGFRβ. Melanoma responses in the phase I study led to this multicenter phase II trial of lenvatinib in separate cohorts of BRAF mutant and BRAF wild-type (wt) melanoma to provide an estimate of efficacy and to identify molecular correlates of clinical benefit. Primary analyses of clinical outcomes for the BRAF wt cohort are reported here; the BRAF mutant cohort will be presented at a later date. Methods: Eligible patients (pts) had stage IV or unresectable stage III BRAF wt melanoma with ≥1 prior treatment (26/96 [27%] pts received ≥3 treatments) and no prior VEGF-targeted therapy. Lenvatinib 24 mg once daily with dose reduction for toxicity was administered until disease progression or unmanageable toxicities. Primary endpoint was response rate by independent review (IRR) using RECIST 1.1. Archival tumor tissue and baseline and posttreatment serum samples were collected for molecular analysis. Results: 93 pts were treated (median [m] age: 64 y; male: 69%; 95% AJCC stage IV). Confirmed partial responses (PRs) were observed in 8 pts (9%) with a clinical benefit rate (CR+PR+durable SD ≥23 wks) of 32% by IRR. mPFS was 3.7 mos (95% CI, 2.5-4.0) by IRR and mOS was 9.5 mos (95% CI, 8.3-12.9); 46% pts required dose reduction for management of toxicity; 12% were withdrawn from therapy due to toxicity. Treatment-related adverse events reported in ≥20% pts included hypertension 59% (34% Gr 3/4), fatigue 58% (16% Gr 3/4), nausea 44% (3% Gr 3/4), diarrhea 43% (2% Gr 3/4), decreased appetite 38%, vomiting 29% (2% Gr 3), dysphonia 27%, and proteinuria and headache 26% each (4% and 1% Gr 3/4). Serum biomarker analysis showed baseline levels of serum angiogenic factors, such as angiopoietin-2, correlated with OS. More extensive biomarker analyses are reported in an accompanying abstract. Conclusions: Lenvatinib administered to pts with advanced BRAF wt melanoma was associated with frequent but manageable toxicity. Clinical benefit was seen in some pts. Predictive biomarkers for response to lenvatinib, such as the serum level of angiogenic factors, may be useful for future clinical trials. Clinical trial information: NCT01136967.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
科研通AI2S应助有丶神采纳,获得10
2秒前
cai发布了新的文献求助100
2秒前
KIKI完成签到,获得积分10
2秒前
不展完成签到 ,获得积分10
3秒前
zwww完成签到,获得积分10
5秒前
小猫最受完成签到,获得积分10
9秒前
Gauss应助哇咔咔采纳,获得30
9秒前
坚强的寒风完成签到,获得积分10
9秒前
乱七八糟发布了新的文献求助10
10秒前
HongJiang发布了新的文献求助10
12秒前
小丸子完成签到 ,获得积分10
13秒前
15884134873发布了新的文献求助10
14秒前
17秒前
Jasper应助科研通管家采纳,获得10
19秒前
斯文败类应助科研通管家采纳,获得10
19秒前
cctv18应助科研通管家采纳,获得10
19秒前
大个应助科研通管家采纳,获得10
19秒前
CipherSage应助科研通管家采纳,获得10
19秒前
脑洞疼应助科研通管家采纳,获得10
19秒前
kento应助科研通管家采纳,获得50
19秒前
科研通AI2S应助科研通管家采纳,获得10
19秒前
老迟到的小蘑菇完成签到,获得积分20
21秒前
22秒前
青瓜大王发布了新的文献求助10
22秒前
23秒前
654-2完成签到,获得积分20
24秒前
科研通AI2S应助苏苏苏采纳,获得10
24秒前
55完成签到,获得积分10
24秒前
魏魏完成签到,获得积分10
25秒前
酷波er应助yu采纳,获得10
26秒前
long完成签到 ,获得积分10
26秒前
654-2发布了新的文献求助10
27秒前
28秒前
暮暮完成签到,获得积分10
29秒前
Vivi给Vivi的求助进行了留言
29秒前
31秒前
眼睛大的初翠完成签到,获得积分10
32秒前
没有逗完成签到,获得积分10
33秒前
梓泽丘墟完成签到,获得积分10
34秒前
高分求助中
Sustainability in ’Tides Chemistry 1500
The ACS Guide to Scholarly Communication 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Handbook of the Mammals of the World – Volume 3: Primates 805
Ethnicities: Media, Health, and Coping 800
Historia de la ciencia jurídica europea 600
Gerard de Lairesse : an artist between stage and studio 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3069575
求助须知:如何正确求助?哪些是违规求助? 2723483
关于积分的说明 7481948
捐赠科研通 2370550
什么是DOI,文献DOI怎么找? 1257057
科研通“疑难数据库(出版商)”最低求助积分说明 609800
版权声明 596861